Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	7	-	-	-
Cost of Revenue	65.74	85.7	51.01	38.94	-
Gross Profit	-65.74	-78.7	-51.01	-38.94	-
Selling, General & Admin	23.39	26.54	20.15	15.72	11.97
Research & Development	-	-	-	-	30.98
Operating Expenses	23.39	26.54	20.15	15.72	42.95
Operating Income	-89.14	-105.24	-71.16	-54.66	-42.95
Interest Expense	-1.59	-1.55	-1.19	-0.16	-
Interest & Investment Income	8.46	11.1	4.11	0.19	1.21
EBT Excluding Unusual Items	-82.27	-95.68	-68.24	-54.63	-41.74
Merger & Restructuring Charges	-1.47	-6.19	-	-	-
Pretax Income	-83.74	-101.87	-68.24	-54.63	-41.74
Net Income	-83.74	-101.87	-68.24	-54.63	-41.74
Net Income to Common	-83.74	-101.87	-68.24	-54.63	-41.74
Shares Outstanding (Basic)	7	7	7	5	4
Shares Outstanding (Diluted)	7	7	7	5	4
Shares Change (YoY)	0.48%	7.70%	27.69%	19.90%	130.58%
EPS (Basic)	-11.49	-14.04	-10.13	-10.35	-9.49
EPS (Diluted)	-11.49	-14.04	-10.13	-10.35	-9.49
Free Cash Flow	-74.24	-83.46	-60.42	-42.75	-37.14
Free Cash Flow Per Share	-10.18	-11.50	-8.97	-8.10	-8.44
Operating Margin	-	-1503.39%	-	-	-
Profit Margin	-	-1455.29%	-	-	-
Free Cash Flow Margin	-	-1192.21%	-	-	-
EBITDA	-88.1	-104.17	-70.14	-53.15	-41.41
D&A For EBITDA	1.04	1.07	1.02	1.51	1.54
EBIT	-89.14	-105.24	-71.16	-54.66	-42.95

Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q